TopFunds

Bristol-Myers Squibb Company

NYSE: BMY

Stock price

60.74 USD

(+Infinity%) NaN day

Drug Manufacturers - General

Financial Performance

Share

5Y price score: (13)

Help

The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.

A score of 100 indicates that the stock did as well as the S&P 500 Index.

A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.

10Y return: 5%

DATE RANGE:

US$ Per
Share

    Time scale:

    By default your notes are visible only to you.

    42.5

    52-week range

    62.8

    60.74

    Your model inputs

    Required return / cost of capital
    %
    FCFF terminal growth rate
    %

    Your fair value & Margin of safety

    To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.

    Forecast:

    Valuation

    Free Cash Flow Yield

    Help
    FCF Yield TTM = Trailing Twelve Months free cash flow per share / current market price per shareLearn more

    9.6 %

    Dividend Yield TTM

    4.1 %

    Market cap $

    $ 124,035

    Price / Earnings TTM

    Help
    P/E TTM = current market price per share / Trailing Twelve Months diluted earnings per shareLearn more

    17.1

    Price / Book TTM

    6.2

    PEG TTM

    Help
    Price/Earnings-to-Growth ratio = P/E TTM divided by most recent annual diluted earnings per share growth rateLearn more

    0.1

    Earnings growth and return

    LTM

    5YR

    10YR

    Total return (price & dividends)

    31.5 %

    6.3 %

    4.9 %

    Free cash flow per share growth

    (8.5) %

    6.9 %

    722.3 %

    Earnings per share growth

    178.2 %

    186.7 %

    255.7 %

    Founded: 1,989

    Employees: 34,100

    Business Summary:Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

    Fair Value Reference Estimate

    Latest Earnings Call Takeaways

    Annual Reports, Presentations And IR Contacts

    Go to the website
    Annual report links (10K)
    2025202420232022202120202019201820172016

    Bristol-Myers Squibb Company — Financial Overview, Stock Price, Market Cap

    Bristol-Myers Squibb Company is a company. Founded in 1989. As of July 20, 2026, the company's market capitalization is $124035331800 with a current stock price of $60.74.